WO2024009205 - STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY
National phase entry is expected:
Publication Number
WO/2024/009205
Publication Date
11.01.2024
International Application No.
PCT/IB2023/056889
International Filing Date
03.07.2023
Title **
[English]
STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY
[French]
FORMULATION LIQUIDE STABLE D'UN ANTICORPS ANTI-Α4SS7
Applicants **
INTAS PHARMACEUTICALS LTD.
Inventors
INGARODIYA, Kinjal
JANGLE, Rahul
GABHALE, Akash
NAIR, Pravin A.
ADHIKARY, Laxmi
Priority Data
202221038828
06.07.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1951 | |
| EPO | Filing, Examination, Granting | 11561 | |
| Japan | Filing, Examination, Granting | 2026 | |
| South Korea | Filing, Examination, Granting | 1765 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,043
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention provides stable liquid formulation of anti-α4ß7 antibody comprising buffer, bulking agent/ stabilizer, viscosity reducer, antioxidant and surfactant, wherein the bulking agent/ stabilizer is sucrose, viscosity reducer is L-lysine HCl and antioxidant is methionine. The stable liquid formulation according to present invention is suitable for subcutaneous administration.[French]
L'invention concerne une formulation liquide stable d'anticorps anti-α4ß7 comprenant un tampon, un agent gonflant/stabilisant, un réducteur de viscosité, un antioxydant et un tensioactif, l'agent gonflant/stabilisant étant le saccharose, le réducteur de viscosité étant la L-lysine HCl et l'antioxydant étant la méthionine. La formulation liquide stable selon la présente invention est appropriée pour une administration sous-cutanée.